Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 14;13:22220. doi: 10.1038/s41598-023-49750-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The results of GO, KEGG, GSEA, TME, immune invasion TMB, and TIDE analyses. (A) GO enrichment analysis revealed the top 10 biological functions in BPs, CCs, and MFs. (B) KEGG analysis revealed significantly enriched pathways. (C, D) GSEA analysis revealed the biological functions and pathways of the high risk group located in the top three. (E) Differences in stromal cells in patients in high and low risk groups. (F) Abundance of immune cell infiltration in all patients. (G, H) Differences in immune cells (B cells memory, T cells CD8, T cells CD4 memory activated, macrophages M0, macrophages M1, dendritic cells resting, and dendritic cells activated) and immune-related pathways (aDCs, APC co-inhibition, macrophages, parainflammation, and Type I IFN Response) in patients in high and low risk groups. (I, J) Somatic mutation in the high and low risk groups. (K) Differences in TMB between the high and low risk groups. (L) A significant difference in survival between the high and low risk groups of patients with TMB was observed. (M) Patients with low TMB and high risk have the worst survival. (N) Differences in TIDE between patients in the high and low risk groups were observed. *p < 0.05, **p < 0.01, ***p < 0.001.